Selected research
Industry Growth & Trends
Global Blood Cancer Drugs Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Blood Cancer Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Blood Cancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Blood Cancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Blood Cancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Blood Cancer Drugs market include Astellas Pharma,, AstraZeneca PLC,, Bayer AG,, Bristol-Myers Squibb Company,, Celgene Corporation,, F.Hoffmann-La Roche,, AbbVie, Amgen, and Pfizer,, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Blood Cancer Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Blood Cancer Drugs market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Blood Cancer Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Blood Cancer Drugs.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Blood Cancer Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Blood Cancer Drugs Market by Company
Astellas Pharma,
AstraZeneca PLC,
Bayer AG,
Bristol-Myers Squibb Company,
Celgene Corporation,
F.Hoffmann-La Roche,
AbbVie
Amgen,
Pfizer,
Eli Lilly,
Novartis
Johnson & Johnson,
Takeda Pharmaceutical Company Ltd,
Blood Cancer Drugs Segment by Type
Blood Chemotherapy Drugs
Blood Targeted Therapy Drugs
Blood Cancer Drugs Segment by Application
lymphoma
Multiple Myeloma
Leukemia
Blood Cancer Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Blood Cancer Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Blood Cancer Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Blood Cancer Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Blood Cancer Drugs companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Blood Chemotherapy Drugs
- Blood Targeted Therapy Drugs
Applications
- lymphoma
- Multiple Myeloma
- Leukemia
Companies covered
- Astellas Pharma,
- AstraZeneca PLC,
- Bayer AG,
- Bristol-Myers Squibb Company,
- Celgene Corporation,
- F.Hoffmann-La Roche,
- AbbVie
- Amgen,
- Pfizer,
- Eli Lilly,
- Novartis
- Johnson & Johnson,
- Takeda Pharmaceutical Company Ltd,
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Blood Cancer Drugs Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Blood Cancer Drugs Market Size by Region (2021-2032)
- 1.4.1 Global Blood Cancer Drugs Market Size by Region (2021-2026)
- 1.4.2 Global Blood Cancer Drugs Market Size by Region (2027-2032)
- 1.5 Key Regions Blood Cancer Drugs Market Size (2021-2032)
- 1.5.1 North America Blood Cancer Drugs Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Blood Cancer Drugs Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Blood Cancer Drugs Market Size Growth Rate (2021-2032)
- 1.5.4 South America Blood Cancer Drugs Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Blood Cancer Drugs Market Size Growth Rate (2021-2032)
2 Blood Cancer Drugs Market by Type
- 2.1 Type Introduction
- 2.1.1 Blood Chemotherapy Drugs
- 2.1.2 Blood Targeted Therapy Drugs
- 2.2 Global Blood Cancer Drugs Market Size by Type
- 2.2.1 Global Blood Cancer Drugs Market Size Overview by Type (2021-2032)
- 2.2.2 Global Blood Cancer Drugs Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Blood Cancer Drugs Market Size Forecasted by Type (2027-2032)
- 2.3 Global Blood Cancer Drugs Market Size by Regions
- 2.3.1 North America Blood Cancer Drugs Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Blood Cancer Drugs Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Blood Cancer Drugs Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Blood Cancer Drugs Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Blood Cancer Drugs Market Size Breakdown by Type (2021-2026)
3 Blood Cancer Drugs Market by Application
- 3.1 Type Introduction
- 3.1.1 lymphoma
- 3.1.2 Multiple Myeloma
- 3.1.3 Leukemia
- 3.2 Global Blood Cancer Drugs Market Size by Application
- 3.2.1 Global Blood Cancer Drugs Market Size Overview by Application (2021-2032)
- 3.2.2 Global Blood Cancer Drugs Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Blood Cancer Drugs Market Size Forecasted by Application (2027-2032)
- 3.3 Global Blood Cancer Drugs Market Size by Regions
- 3.3.1 North America Blood Cancer Drugs Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Blood Cancer Drugs Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Blood Cancer Drugs Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Blood Cancer Drugs Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Blood Cancer Drugs Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Blood Cancer Drugs Industry Trends
- 4.2 Blood Cancer Drugs Industry Drivers
- 4.3 Blood Cancer Drugs Industry Opportunities and Challenges
- 4.4 Blood Cancer Drugs Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Blood Cancer Drugs Revenue (2021-2026)
- 5.2 Global Blood Cancer Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Blood Cancer Drugs Key Company Headquarters & Area Served
- 5.4 Global Blood Cancer Drugs Company, Product Type & Application
- 5.5 Global Blood Cancer Drugs Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Blood Cancer Drugs Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Blood Cancer Drugs Players Market Share by Revenue in 2025
- 5.6.3 2025 Blood Cancer Drugs Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Astellas Pharma,
- 6.1.1 Astellas Pharma, Company Information
- 6.1.2 Astellas Pharma, Business Overview
- 6.1.3 Astellas Pharma, Blood Cancer Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Astellas Pharma, Blood Cancer Drugs Product Portfolio
- 6.1.5 Astellas Pharma, Recent Developments
- 6.2 AstraZeneca PLC,
- 6.2.1 AstraZeneca PLC, Company Information
- 6.2.2 AstraZeneca PLC, Business Overview
- 6.2.3 AstraZeneca PLC, Blood Cancer Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 AstraZeneca PLC, Blood Cancer Drugs Product Portfolio
- 6.2.5 AstraZeneca PLC, Recent Developments
- 6.3 Bayer AG,
- 6.3.1 Bayer AG, Company Information
- 6.3.2 Bayer AG, Business Overview
- 6.3.3 Bayer AG, Blood Cancer Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Bayer AG, Blood Cancer Drugs Product Portfolio
- 6.3.5 Bayer AG, Recent Developments
- 6.4 Bristol-Myers Squibb Company,
- 6.4.1 Bristol-Myers Squibb Company, Company Information
- 6.4.2 Bristol-Myers Squibb Company, Business Overview
- 6.4.3 Bristol-Myers Squibb Company, Blood Cancer Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Bristol-Myers Squibb Company, Blood Cancer Drugs Product Portfolio
- 6.4.5 Bristol-Myers Squibb Company, Recent Developments
- 6.5 Celgene Corporation,
- 6.5.1 Celgene Corporation, Company Information
- 6.5.2 Celgene Corporation, Business Overview
- 6.5.3 Celgene Corporation, Blood Cancer Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Celgene Corporation, Blood Cancer Drugs Product Portfolio
- 6.5.5 Celgene Corporation, Recent Developments
- 6.6 F.Hoffmann-La Roche,
- 6.6.1 F.Hoffmann-La Roche, Company Information
- 6.6.2 F.Hoffmann-La Roche, Business Overview
- 6.6.3 F.Hoffmann-La Roche, Blood Cancer Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 F.Hoffmann-La Roche, Blood Cancer Drugs Product Portfolio
- 6.6.5 F.Hoffmann-La Roche, Recent Developments
- 6.7 AbbVie
- 6.7.1 AbbVie Company Information
- 6.7.2 AbbVie Business Overview
- 6.7.3 AbbVie Blood Cancer Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 AbbVie Blood Cancer Drugs Product Portfolio
- 6.7.5 AbbVie Recent Developments
- 6.8 Amgen,
- 6.8.1 Amgen, Company Information
- 6.8.2 Amgen, Business Overview
- 6.8.3 Amgen, Blood Cancer Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Amgen, Blood Cancer Drugs Product Portfolio
- 6.8.5 Amgen, Recent Developments
- 6.9 Pfizer,
- 6.9.1 Pfizer, Company Information
- 6.9.2 Pfizer, Business Overview
- 6.9.3 Pfizer, Blood Cancer Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Pfizer, Blood Cancer Drugs Product Portfolio
- 6.9.5 Pfizer, Recent Developments
- 6.10 Eli Lilly,
- 6.10.1 Eli Lilly, Company Information
- 6.10.2 Eli Lilly, Business Overview
- 6.10.3 Eli Lilly, Blood Cancer Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Eli Lilly, Blood Cancer Drugs Product Portfolio
- 6.10.5 Eli Lilly, Recent Developments
- 6.11 Novartis
- 6.11.1 Novartis Company Information
- 6.11.2 Novartis Business Overview
- 6.11.3 Novartis Blood Cancer Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 Novartis Blood Cancer Drugs Product Portfolio
- 6.11.5 Novartis Recent Developments
- 6.12 Johnson & Johnson,
- 6.12.1 Johnson & Johnson, Company Information
- 6.12.2 Johnson & Johnson, Business Overview
- 6.12.3 Johnson & Johnson, Blood Cancer Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.12.4 Johnson & Johnson, Blood Cancer Drugs Product Portfolio
- 6.12.5 Johnson & Johnson, Recent Developments
- 6.13 Takeda Pharmaceutical Company Ltd,
- 6.13.1 Takeda Pharmaceutical Company Ltd, Company Information
- 6.13.2 Takeda Pharmaceutical Company Ltd, Business Overview
- 6.13.3 Takeda Pharmaceutical Company Ltd, Blood Cancer Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.13.4 Takeda Pharmaceutical Company Ltd, Blood Cancer Drugs Product Portfolio
- 6.13.5 Takeda Pharmaceutical Company Ltd, Recent Developments
7 North America
- 7.1 North America Blood Cancer Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Blood Cancer Drugs Market Size by Country (2021-2026)
- 7.3 North America Blood Cancer Drugs Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Blood Cancer Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Blood Cancer Drugs Market Size by Country (2021-2026)
- 8.3 Europe Blood Cancer Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Blood Cancer Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Blood Cancer Drugs Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Blood Cancer Drugs Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Blood Cancer Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Blood Cancer Drugs Market Size by Country (2021-2026)
- 10.3 South America Blood Cancer Drugs Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Blood Cancer Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Blood Cancer Drugs Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Blood Cancer Drugs Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst